Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H21F3O5S |
| Molecular Weight | 430.438 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@@H]1CC2=C(C1)C(OC3=CC(OS(=O)(=O)CCCC(F)(F)F)=CC=C3)=CC=C2
InChI
InChIKey=XJURALZPEJKKOV-CQSZACIVSA-N
InChI=1S/C20H21F3O5S/c21-20(22,23)8-3-9-29(25,26)28-17-6-2-5-16(12-17)27-19-7-1-4-15-10-14(13-24)11-18(15)19/h1-2,4-7,12,14,24H,3,8-11,13H2/t14-/m1/s1
| Molecular Formula | C20H21F3O5S |
| Molecular Weight | 430.438 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:36:49 GMT 2025
by
admin
on
Mon Mar 31 22:36:49 GMT 2025
|
| Record UNII |
SRX4T6TMUS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/08/560
Created by
admin on Mon Mar 31 22:36:49 GMT 2025 , Edited by admin on Mon Mar 31 22:36:49 GMT 2025
|
||
|
WIKIPEDIA |
Designer-drugs-BAY-38-7271
Created by
admin on Mon Mar 31 22:36:49 GMT 2025 , Edited by admin on Mon Mar 31 22:36:49 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9845561
Created by
admin on Mon Mar 31 22:36:49 GMT 2025 , Edited by admin on Mon Mar 31 22:36:49 GMT 2025
|
PRIMARY | |||
|
SRX4T6TMUS
Created by
admin on Mon Mar 31 22:36:49 GMT 2025 , Edited by admin on Mon Mar 31 22:36:49 GMT 2025
|
PRIMARY | |||
|
DTXSID701010009
Created by
admin on Mon Mar 31 22:36:49 GMT 2025 , Edited by admin on Mon Mar 31 22:36:49 GMT 2025
|
PRIMARY | |||
|
100000181847
Created by
admin on Mon Mar 31 22:36:49 GMT 2025 , Edited by admin on Mon Mar 31 22:36:49 GMT 2025
|
PRIMARY | |||
|
BAY 38-7271
Created by
admin on Mon Mar 31 22:36:49 GMT 2025 , Edited by admin on Mon Mar 31 22:36:49 GMT 2025
|
PRIMARY | Originally synthesized by chemist Wayne E. Kenney, BAY 38-7271 (KN 38-7271) is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury. It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB1 and CB2 receptors, with Ki values of 2.91nM at CB1 and 4.24nM at CB2. It has now been licensed to KeyNeurotek Pharmaceuticals for clinical development, and is currently in Phase II trials. But its development appears stopped. | ||
|
212188-60-8
Created by
admin on Mon Mar 31 22:36:49 GMT 2025 , Edited by admin on Mon Mar 31 22:36:49 GMT 2025
|
PRIMARY | |||
|
BAY-38-7271
Created by
admin on Mon Mar 31 22:36:49 GMT 2025 , Edited by admin on Mon Mar 31 22:36:49 GMT 2025
|
PRIMARY | BAY 38-7271 (KN 38-7271) CAS: 212188-60-8 | ||
|
SUB195628
Created by
admin on Mon Mar 31 22:36:49 GMT 2025 , Edited by admin on Mon Mar 31 22:36:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
